Lei Lei Wu is a News Reporter at Endpoints News. She specializes in reporting on cell therapy, genetic medicines, and the science behind drug development, with a keen focus on pharmaceuticals and healthcare systems. Lei Lei's insights and analyses are featured in Endpoints News, where she also covers medical meetings and clinical trial results.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lei Lei Wu's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly on biotechnology, pharmaceutical companies, gene therapy, clinical trials, and drug development. The majority of her articles are based on press releases and cite data.
Given this focus, she would likely be interested in receiving pitches related to new developments in biotechnology or pharmaceuticals backed by solid data or press releases. Pitches offering insights from experts within these fields regarding groundbreaking studies or significant advancements in drug development may resonate with her. Additionally, providing access to exclusive data or early access to important press releases could enhance the effectiveness of outreach efforts.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lei Lei Wu
Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI
By: Max Gelman
Welcome back to another edition of Endpoints Weekly. My usual colleague Nicole DeFeudis is out this week, so I've assembled the Weekly with the help …
BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell lymphoma trial.
The FDA gave the go-ahead to Orca Bio's T cell therapy that would reduce transplant-related complications for blood cancer patients.
By: Lei Lei Wu
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows more crowded.
By: Lei Lei Wu
Satellos shares adult TRAILHEAD data on Duchenne pill SAT-3247 ahead of a potentially pivotal BASECAMP readout in children by year-end.
By: Lei Lei Wu
The decision comes after tominersen did no better than placebo in a Phase 2 trial with patients in the earliest stages of the disease.
By: Lei Lei Wu
Cellular Intelligence's STEM-PD data, presented at ISSCR and in Nature Medicine, shows safety signals and reduced medication use in Parkinson's patients ahead of a planned Phase 2.
By: Lei Lei Wu
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen, targeting a first IND within 18 months.
AdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment.
